Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
MiR-641 participates in the progression of breast cancer by modulation of RELN expression
Abstract
Purpose: To examine the role of micro-ribonucleic acid 641 (miR-641) in breast cancer, and to uncover its possible molecular mechanism.
Methods: MiR-641 expressions in breast cancer cell lines and tissues were determined using Real-time fluorescence quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and the diagnostic potential value of miR-641 was assessed using receiver operating characteristic (ROC) curves. The survival of the patients was analyzed using Kaplan-Meier, and the cell viability and migration capacity were evaluated using Transwell and cell counting kit-8 (CCK-8) assay, and the downstream target gene of miR-641 was confirmed via dual-luciferase reporter gene assay. Finally, reversal assay was employed to corroborate the molecular mechanism that affects cell proliferation and migration via modulation of RELN.
Results: MiR-641 was lowly expressed in breast cancer cell lines and tissues, and its expression in the metastasizing group was lower than that in the matched group (p < 0.05). It was also observed that miR-641 expression gradually decreased as the breast cancer advanced. Moreover, lower miR-641 expression revealed a poor prognosis, and up-regulating miR-641 suppressed the proliferative and migrative capacities of breast cancer cells. It was proven that RELN is a target gene of miR-641. RELN expression rose in breast cancer, and it was evidently and negatively correlated with that of miR-641. Finally, miR-641 regulated RELN, and it affected the proliferation and migration of cells.
Conclusion: MiR-641 has an obviously decreased expression level in breast cancer, and facilitates the proliferative and migrative capacity of breast cancer cells probably by modulating the RELN expression. This study may provide new targets for the treatment of breast cancer.
